Zacks Rating on Clovis Oncology (CLVS)

Clovis Oncology (CLVS) : 3 brokerage houses believe that Clovis Oncology (CLVS) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Clovis Oncology (CLVS). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 6 Wall Street Analysts endorse the stock as a Buy with a rating of 2.

Clovis Oncology (CLVS) : The highest level Clovis Oncology (CLVS) is projected to reach is $30 for the short term and the lowest estimate is at $14. The consolidated price target from 6 rating analysts who initiate coverage on the stock is $21.17 and the possibility the share price can swing is $6.05.


Shares of Clovis Oncology, Inc. rose by 31.9% in the last five trading days and 65.56% for the last 4 weeks. Clovis Oncology, Inc. is up 47.82% in the last 3-month period. Year-to-Date the stock performance stands at -34.2%. Clovis Oncology (NASDAQ:CLVS): stock turned positive on Tuesday. Though the stock opened at $18.3, the bulls momentum made the stock top out at $24.9695 level for the day. The stock recorded a low of $16.61 and closed the trading day at $23.03, in the green by 27.24%. The total traded volume for the day was 17,463,758. The stock had closed at $18.1 in the previous days trading.

Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.